As of November 6, 2026, GRI Bio, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 6 filings are on record since December 17, 2025 (Schedule 13G/A, August 13, 2026).
Sell to companies like GRI Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Mitchell P. Kopin · Sole voting: 0 · Shared voting: 93,005 · Sole dispositive: 0 · Shared dispositive: 93,005 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Mitchell P. Kopin · Percent: 5.9% · SCHEDULE 13G/A
- · Holder: Mitchell P. Kopin · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: Lincoln Alternative Strategies LLC · Percent: 0% · SCHEDULE 13G/A
- · Holder: Lincoln Alternative Strategies LLC · Percent: 11.83% · SCHEDULE 13G
GRI Bio, Inc. has 6 Schedule 13D or 13G filings on record since 2025-12-17. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 4.99% | 93,005 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 | |
| Lincoln Alternative Strategies LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-30 |
Holding shares or following this stake? See who's behind GRI Bio, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on GRI Bio, Inc. and the records around it.
GRI Bio, Inc. elsewhere on the record
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch GRI Bio, Inc.
Get an email when GRI Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on GRI Bio, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on GRI Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GRI Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Mitchell P. Kopin | 0 | 93,005 | 0 | 93,005 | SCHEDULE 13G/A, 2026-08-13 |
| Daniel B. Asher | 0 | 93,005 | 0 | 93,005 | SCHEDULE 13G/A, 2026-08-13 |
| Intracoastal Capital LLC | 0 | 93,005 | 0 | 93,005 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies GRI Bio, Inc. by CUSIP 3622AW502 and gives its principal executive office as 2223 Avenida de la Playa, La Jolla, CA 92037 (SCHEDULE 13G/A, 2026-08-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-17 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G |
| 2025-12-29 | Lincoln Alternative Strategies LLC | 11.83% | SCHEDULE 13G |
| 2026-02-10 | Lincoln Alternative Strategies LLC | 0% | SCHEDULE 13G/A |
| 2026-02-13 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G/A |
| 2026-05-13 | Mitchell P. Kopin | 5.9% | SCHEDULE 13G/A |
| 2026-08-13 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G/A |
Also on the record for GRI Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for GRI Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.